ArticleAnnals of surgical oncology2025
Role of Lateral Pelvic Lymph Node Dissection Following Neoadjuvant Chemoradiation Therapy in Rectal Cancer: A Multicenter Retrospective Study (KROG 22-09).
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impacts of neoadjuvant therapy on subsequent surgical difficulty, safety, and outcomes in locally advanced rectal cancer: a narrative review.Journal of gastrointestinal oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLateral pelvic lymph node (LPLN) metastasis is a poor prognostic factor in rectal cancer, but the optimal management strategy is debated. This multicenter retrospective study investigated the role of LPLN dissection (LPLND), with total mesorectal excision (TME), after neoadjuvant chemoradiation therapy (nCRT), aiming to identify patients who may benefit from LPLND. PATIENTS AND
methodsA total of 559 patients with locally advanced rectal cancer and LPLN involvement from 2009 to 2018 were included (KROG 22-09). Patients underwent either LPLND (n = 189) or no LPLND (n = 370) with TME post-nCRT. The lateral pelvic recurrence-free rate (LRFR) and recurrence-free survival (RFS) were assessed. Propensity score matching (PSM) was used to minimize confounders.
resultsBefore PSM, the LPLND group had more advanced disease, higher tumor marker levels, and larger LPLNs before and after nCRT (median longest short axis [LSA]: 8.5 versus 6.3 mm, p < 0.001; 5.0 versus 4.2 mm, p < 0.001, respectively). With a median follow-up of 62 (interquartile range, 43-95) months, there was no difference in the 5-year LRFR (89.3% versus 91.9%, p = 0.130) and RFS (65.1% versus 72.0%, p = 0.083) between the LPLND and no LPLND groups. PSM analysis (130 patients) also showed no difference in LRFR (93.5% versus 89.2%, p = 0.450) and RFS (68.6% versus 67.2%, p = 0.710). Notably, LPLND significantly improved LRFR in patients with post-nCRT LPLN LSA ≥ 5 mm (98.0% versus 80.9%, p = 0.033).
conclusionsLPLND did not significantly reduce pelvic recurrence or improve survival in patients treated with nCRT. However, LPLND may benefit patients with post-nCRT LPLN LSA ≥ 5 mm, suggesting that patient selection is crucial.
Indexed as
Identifiers
40911237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.